Receptor lymphoma t cell. Medical search. Frequent questions

This ulcerated nodule of localized primary cutaneous CD30+ anaplastic large cell lymphoma is relatively nonspecific in appearance. (medscape.com)
This gene is also a translocation partner in anaplastic large cell lymphoma and inflammatory myofibroblastic tumor cases, where a t(2;17)(p23;q25) translocation has been identified with the anaplastic lymphoma kinase (ALK) gene on chromosome 2, and a t(8;17)(q24;q25) translocation has been identified with the MYC gene on chromosome 8. (cancerindex.org)

The activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) relies on chronic active B-cell receptor (BCR) signaling. (arizona.edu)
CD19-directed CAR T therapy is now approved to treat a range of B-cell malignancies including childhood B cell acute lymphoblastic leukemia and adult large B cell lymphoma, primary mediastinal large B cell lymphoma, mantle cell lymphoma and follicular lymphoma. (lls.org)
Background/Aim: Chimeric antigen receptor (CAR) T-cell therapy is a novel cell therapy for treating hematological cancers including multiply relapsed large B-cell lymphoma in adults. (uwaterloo.ca)
Emerging synthetic drugs for the treatment of diffuse large B-cell lymphoma. (moffitt.org)
Chimeric antigen receptor T (CART) cell therapy targeting the B cell specific differentiation antigen CD19 has shown clinical efficacy in a subset of relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL) patients. (frontiersin.org)
Diffuse large B cell lymphoma (DLBCL) represents the most frequent form of non-Hodgkin's lymphoma (NHL). (frontiersin.org)
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer of lymphocytes, and a large proportion of patients are either unresponsive or develop resistance towards R-CHOP-the standard treatment regimen. (news-medical.net)
New review article in Chinese Medical Journal details the potential mechanisms of resistance to the R-CHOP chemotherapy regimen in patients with diffuse large B-cell lymphoma. (news-medical.net)
Of them, diffuse large B-cell lymphoma (DLBCL) is the most common Non-Hodgkins lymphoma and is highly aggressive and fast-growing. (news-medical.net)
Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma. (bvsalud.org)

In this review, we aim to summarize the composition of CAR-T cell and its application in the treatment of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL), multiple myeloma (MM), and acute myeloid leukemia (AML). (hindawi.com)
Dr. Schiller is a well-published clinical investigator in acute and chronic leukemias, multiple myeloma, and other hematologic malignancies, as well as in stem cell and bone marrow transplantation. (uclahealth.org)
His research projects include clinical studies of new drugs, therapies, and bone marrow/stem cell transplantation for patients with malignancies of the blood or bone marrow such as leukemia, multiple myeloma, and lymphoma. (uclahealth.org)
He has also carried out work with purified stem cell transplantation for multiple myeloma. (uclahealth.org)
While all prior approvals with CAR T have directed the engineered T-cells to CD19, a marker on the surface of malignancies derived from B-cells, this is the first approval of a B-cell maturation antigen (BCMA)-directed CAR T. Idecabtegene vicleucel or ide-cel (Abecma) is the first approval of a CAR T for multiple myeloma. (lls.org)
Multiple myeloma is a cancer derived from a specialized type of white blood cell called a plasma cells. (lls.org)
are developing the drug to target B-cell malignancies, including various forms of leukemia, lymphoma and multiple myeloma. (nih.gov)
Chimeric antigen receptor (CAR) T-cell therapy is an example of how immunotherapy is revolutionizing the treatment of hematologic malignancies with unprecedented response rates in patients with relapsed/refractory lymphoma, multiple myeloma, and acute lymphoblastic leukemia. (ajmc.com)
ANLL), and limited evidence for acute lymphocytic leukaemia (ALL), chronic lymphocytic leukaemia (CLL), multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). (cdc.gov)

KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. (cdc.gov)
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. (cdc.gov)

Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma. (moffitt.org)
One of the most exciting areas of immunotherapy is CAR (chimeric antigen receptor) T-cell therapy. (healthwellfoundation.org)
CAR (chimeric antigen receptor) T-cell therapy is the latest wave in hematology and has been validated in various forms of leukemia and lymphoma . (medscape.com)

Diffuse large B-cell lymphomas (DLBCL), which were studied in this trial, are aggressive cancers that grow rapidly and represent 30 percent to 40 percent of newly diagnosed lymphomas. (nih.gov)

Collectively, CTCL is classified as a type of non-Hodgkin lymphoma (NHL). (medscape.com)
Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial. (qxmd.com)
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. (canadianhematologytoday.com)
3-year follow-up analysis of ZUMA-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). (canadianhematologytoday.com)
This approval comes on the heels of two new indications for CD19-directed CAR T: axicabtagene ciloleucel (Yescarta®) to treat resistant forms of indolent non-Hodgkin lymphoma, as well as the first approval of new CD19-directed CAR T, lisocabtagene maraleucel (Breyanzi®), for resistant forms of aggressive non-Hodgkin lymphoma. (lls.org)
Which medications in the drug class Antineoplastic Agents, mTOR Kinase Inhibitors are used in the treatment of Non-Hodgkin Lymphoma (NHL)? (medscape.com)
Hodgkin lymphoma with cutaneous involvement. (medscape.com)
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Health Professional Version. (medscape.com)
Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. (medscape.com)
Cancer Stat Facts: Non-Hodgkin Lymphoma. (medscape.com)
Time trends in risk and risk determinants of non-hodgkin lymphoma in solid organ transplant recipients. (medscape.com)
Computed tomography-based tumor volume in non-Hodgkin lymphoma: clinical correlation and comparison with magnetic resonance imaging. (medscape.com)
For other discussions on lymphoma, see the overview topic Non-Hodgkin Lymphoma . (medscape.com)
The major types are Hodgkin lymphoma Non-Hodgkin lymphoma See table Comparison of Hodgkin. (msdmanuals.com)
Hodgkin Lymphoma Hodgkin lymphoma is a localized or disseminated malignant proliferation of cells of the lymphoreticular system, primarily involving lymph node tissue, spleen, liver, and bone marrow. (msdmanuals.com)
Non-Hodgkin lymphoma is not one disease but rather a category of lymphocyte cancers with a number of subgroups largely divided into aggressive and indolent types. (msdmanuals.com)
Non-Hodgkin lymphoma is the 2nd most common cancer in HIV-infected patients Non-Hodgkin lymphoma AIDS-defining cancers in patients infected with HIV are Kaposi sarcoma Lymphoma, Burkitt (or equivalent term) Lymphoma, immunoblastic (or equivalent term) Lymphoma, primary, of central nervous system read more , and some AIDS patients present with lymphoma. (msdmanuals.com)
Indeed, patients with non-Hodgkin lymphoma should generally be screened for HIV and hepatitis viruses. (msdmanuals.com)
Also, patients with a first-degree relative with Hodgkin or non-Hodgkin lymphoma have an increased risk of non-Hodgkin lymphoma. (msdmanuals.com)

Murine thymic lymphomas as model tumors for T-cell studies. (wikidata.org)
ADI-270 has demonstrated a highly differentiated profile stemming from its unique engineering, including targeting via a CAR that incorporates CD27, addition of dominant negative TGF beta receptor armoring, complimentary innate anti-tumor activity of the gamma delta 1 T cells and tissue tropism to solid tumors. (businesswire.com)
ADI-270 is designed to home to solid tumors, with a highly specific targeting moiety for CD70 and an armoring technology of dominant negative TGF beta receptor to address immunosuppressive factors in the tumor microenvironment. (businesswire.com)
Data demonstrated intrinsic targeting of patient-derived tumors by gamma delta T cells. (businesswire.com)
Over one-fifth of ABC tumors have mutations that alter the activity of the B-cell receptor. (nih.gov)
There is compelling clinical and experimental evidence to suggest that natural killer (NK) cells play a critical role in the recognition and eradication of tumors. (frontiersin.org)
However, as tumors progress, cancerous cells develop immunosuppressive mechanisms that circumvent NK cell-mediated killing, allowing for tumor escape and proliferation. (frontiersin.org)
However, a class of important immune-modulators is conspicuously absent: agents that utilize the power of innate immune cells to eradicate tumors. (frontiersin.org)
Genomic assays have had a powerful influence on the management of early-stage breast cancer, particularly estrogen receptor-positive tumors. (ascopost.com)
Overview of Lymphoma Lymphomas are a heterogeneous group of tumors arising in the reticuloendothelial and lymphatic systems. (msdmanuals.com)

T cell immune protection plays a pivotal role in the treatment of patients with hematological malignancies. (hindawi.com)
However, T cell exhaustion might lead to the possibility of immune escape of hematological malignancies. (hindawi.com)
Adoptive cell therapy (ACT) with chimeric antigen receptor T (CAR-T) cells can restore the activity of exhausted T cell through reprogramming and is widely used in the treatment of relapsed/refractory (r/r) hematological malignancies. (hindawi.com)
However, CAR-T cells can also produce some adverse events after treatment of hematological malignancies, such as cytokine release syndrome (CRS), neurotoxicity, and on-target/off-tumor toxicity, which may cause systemic immune stress inflammation, destruction of the blood-brain barrier, and even normal tissue damage. (hindawi.com)
Traditionally, the treatment of hematological malignancies is administrated by chemotherapy, radiotherapy, and stem cell transplantation. (hindawi.com)
It is noted that T cell has great potential for immunotherapy of hematological malignancies. (hindawi.com)
In addition, the isolation and storage of umbilical cord blood hematopoietic stem cells have been used to rebuild the immune system for the treatment of hematological malignancies and might be promising for the dynamic equilibrium expansion of functional T cells [ 12 ]. (hindawi.com)
Adoptive T-cell therapy with anti-CD19 chimeric antigen receptor (CAR)-expressing T cells is a new approach for treating advanced B-cell malignancies. (ashpublications.org)
12 , 13 Clinical trials in which patients with advanced B-cell malignancies receive T cells expressing anti-CD19 CARs are in early stages, and it is not known whether adoptive transfer of T cells targeting this self-antigen will be an effective therapy for B-cell malignancies. (ashpublications.org)
Dr. Dong's clinical interest is in lymphoid malignancies, including B-cell and T-cell lymphomas. (moffitt.org)
Research in CAR T-cell therapy is expected to improve tolerability and expand indications to more types of malignancies and earlier phases of disease. (ajmc.com)
2,3 Cellular therapy centers, manufacturers, payers, and policy makers will need to work together to address barriers to care as new CAR T-cell products with improved efficacy and tolerability are approved for use in more diverse malignancies. (ajmc.com)
The Food and Drug Administration (FDA) has received reports of T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies such as idecabtagene vicleucel injection. (medlineplus.gov)

Novel understanding in the interaction between immune system and cancer cells of the patient holds great promise for immunotherapy development [ 4 - 6 ]. (hindawi.com)
Novel use of targeted therapies and immunotherapy in lymphoma. (cancer.gov)
Vγ9Vδ2 T cells are promising candidates for cellular tumor immunotherapy. (nature.com)
To apply allogeneic Vγ9Vδ2 T cells in adoptive immunotherapy, the methodology used to obtain adequate cell numbers with optimal effector function in vitro needs to be optimized, and clinical safety and efficacy also need to be proven. (nature.com)
Our clinical studies underscore the safety and efficacy of allogeneic Vγ9Vδ2 T-cell immunotherapy, which will inspire further clinical investigations and eventually benefit cancer patients. (nature.com)
In this respect, the introduction of checkpoint inhibitors to unleash the activity of tumor-reactive T cells has been a milestone in cancer immunotherapy. (nature.com)
This type of treatment is known as adoptive immunotherapy and the cells that are infused into the patients are known as universal chimeric antigen receptor T cells (UCAR T cells). (upenn.edu)
instead of targeting tumor cells, the goal of immunotherapy is to augment and expand the immune system's intrinsic antitumor response. (frontiersin.org)
Neoadjuvant immunotherapy with the programmed cell death protein 1 (PD-1) inhibitor nivolumab (Opdivo) is safe and feasible in early-stage non-small cell lung cancer (NSCLC). (ascopost.com)
Immunotherapy with an anti-programmed cell death protein 1 (PD-1) inhibitor-pembrolizumab (Keytruda)-showed encouraging responses in patients with advanced cutaneous T-cell lymphoma (either mycosis fungoides or Sézary syndrome). (ascopost.com)
Idecabtagene vicleucel injection is in a class of medications called autologous cellular immunotherapy, a type of medication prepared using cells from the patient's own blood. (medlineplus.gov)

We speculated that binding of lymphoma BCRs to self-antigens initiates and maintains chronic active BCR signaling in ABC DLBCL. (arizona.edu)
Hence, a diverse set of self-antigens is responsible for maintaining the malignant survival of ABC DLBCL cells. (arizona.edu)
Blood cell and serum markers, along with clinical data of DLBCL patients who were scheduled for CART cell therapy were evaluated to search for biomarkers predicting CART cell responsiveness. (frontiersin.org)
Compared to healthy controls (n=24), DLBCL patients (n=33) showed significant lymphopenia, due to low CD3 + CD4 + T helper and CD3 - CD56 + NK cell counts, while cytotoxic CD3 + CD8 + T cell counts were similar. (frontiersin.org)
Low frequency of differentiated CD3 + CD27 - CD28 - T cells at leukapheresis represents a novel pre-infusion blood biomarker predicting a favorable response to CART cell treatment in r/r DLBCL patients. (frontiersin.org)
DLBCL originates from B cells, which play a crucial role in the body's immune response. (nih.gov)
The activated B-cell (ABC) subtype of DLBCL accounts for approximately 40 percent of cases and has the poorest clinical outcome with current therapy. (nih.gov)
Remissions were also observed in patients with non-ABC DLBCL, suggesting a broader role for the B-cell receptor pathway in this type of lymphoma. (nih.gov)

Classic follicular (FL) and marginal zone (MZL) lymphomas are the primary indolent non-Hodgkin lymphomas (iNHL). (canadianhematologytoday.com)
Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. (canadianhematologytoday.com)
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. (canadianhematologytoday.com)
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. (canadianhematologytoday.com)
Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial. (canadianhematologytoday.com)
Molecular features of high-risk follicular lymphoma. (cancer.gov)
In dogs, high grade (large cell type effacing normal node architecture) histologic subtypes are reported to be more responsive to therapy than low grade (follicular growth within the node) subtypes. (vin.com)
Follicular lymphoma international prognostic index. (medscape.com)

Hallberg, B. & Palmer, R. H. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. (nature.com)
ALK , the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). (nature.com)
Several small molecule tyrosine kinase inhibitors, which block signaling pathways downstream from the B cell receptor, are in active clinical development. (wustl.edu)
B cell antigen receptor desensitization: disruption of receptor coupling to tyrosine kinase activation. (nationaljewish.org)
This research identified the enzyme Bruton's tyrosine kinase (BTK) as a key element in the B-cell receptor pathway that is required to maintain the survival of ABC lymphoma cells. (nih.gov)

A collaboration of international experts is tackling the challenges involved in understanding and managing the treatment of cutaneous lymphomas. (ascopost.com)
Rook AH, Yoo EK, Grossman DJ, Kao DM, Fox FE, Niu Z. Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma. (medscape.com)
Herrmann JJ, Roenigk HH Jr, Hönigsmann H. Ultraviolet radiation for treatment of cutaneous T-cell lymphoma. (medscape.com)
Update on treatment of cutaneous T-cell lymphoma. (medscape.com)

Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. (canadianhematologytoday.com)
The frequency of cutaneous lymphomas is 0.3 case per 100,000 population per year, with 10% (in the United States) to 20% (in Europe) being cutaneous B-cell lymphomas (CBCLs), marginal zone lymphomas, or follicle center lymphomas (FCLs). (medscape.com)

Fusion of a kinase gene, ALK , to a nucleolar protein gene, NPM , in non-Hodgkin's lymphoma. (nature.com)
Anaplastic lymphoma kinase (ALK) protein may be detected in most cases (60-70%) of systemic ALCL by immunohistochemistry. (medscape.com)
The erythropoietin receptor (EpoR) is a protein that in humans is encoded by the EPOR gene. (wikipedia.org)
EpoR is a 52kDa peptide with a single carbohydrate chain resulting in an approximately 56-57 kDa protein found on the surface of EPO responding cells. (wikipedia.org)
Cluster of Differentiation 79 (CD79) is a transmembrane protein found exclusively in B cells that is the transducer component of B-cell receptor (BCR), generating a signal following recognition of antigen by the BCR. (nationaljewish.org)
Hyperproteinemia is a rare finding, and is secondary to protein production by tumor cells. (vin.com)
The protein encoded by P2RY8 gene is composed of 359-amino acids and belongs to the P2Y family of G-protein coupled receptors that are preferentially activated by adenosine and uridine nucleotides. (atlasgeneticsoncology.org)
The recent FDA approvals of the programmed cell death protein 1 (PD-1)-targeted checkpoint inhibitors pembrolizumab and nivolumab mark the latest successes in the rapidly expanding field of cancer immunotherapies. (frontiersin.org)
This complex inhibits mammalian target of rapamycin (mTOR) kinase, a key protein in cells that regulate the gene translation responsible for cell-cycle regulation. (medscape.com)

Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. (canadianhematologytoday.com)
Effectiveness of CAR-T therapies in the general population of lymphoma patients may differ from effectiveness demonstrated in trials. (rand.org)
His areas of interest include the use of novel therapies and drug combinations for the treatment of lymphomas as well as novel methods of molecular monitoring of disease and response to treatment, such as circulating tumor DNA (ctDNA). (cancer.gov)
I have expertise in novel therapies for acute myeloid leukemia, stem cell mobilization and homing, as well as stem cell transplantation. (rochester.edu)
REDWOOD CITY, Calif. & BOSTON--( BUSINESS WIRE )--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2023. (businesswire.com)
These results illustrate how an understanding of the molecular machinery inside a cancer cell can lead to new therapies which can kill tumor cells while sparing normal cells, thus greatly reducing toxicities for patients," said Staudt. (nih.gov)
While effective, broad use of CAR T-cell therapies is limited by potential for life-threatening toxicities, challenges related to manufacturing a patient-specific product, high costs and inadequate reimbursement, and incomplete or unsustained disease response. (ajmc.com)
Managed care professionals should have an understanding of the clinical trial data and place in therapy in lymphoma, myeloma, and acute lymphoblastic leukemia as well as guideline recommendations for adverse effect management associated with CAR T-cell therapies. (ajmc.com)
CAR T-cell therapies are limited by the potential to cause life-threatening toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). (ajmc.com)
Emerging new therapies for cutaneous T-cell lymphoma. (medscape.com)

It is a member of the cytokine receptor family. (wikipedia.org)
The known side-effects for CAR T therapy were reported for ide-cel with marked cytokine release syndrome (CRS) and CAR T cell-associated neurotoxicity, occurring in 85% and 28% of patients, respectively, both of which were usually transient. (lls.org)
Effects of hematopoietic stem cell adhesion on marrow stromal cell cytokine p. (rochester.edu)
We observed that all the venetoclax-resistant T-ALL cell lines displayed non-universal changes in the expression of BCL2 family members and cancer stem cell markers, along with specific enrichment of cytokine signaling pathways. (lu.se)

Related articles include Cutaneous B-Cell Lymphoma and Cutaneous Pseudolymphoma . (medscape.com)
The diagnosis of CBCL is established by analysis of skin biopsy specimen, using histomorphology and cytomorphology, immunohistochemistry and phenotypic features, and genotyping and cytogenetic studies (see Workup of Cutaneous B-Cell Lymphoma). (medscape.com)

Adoptive T-cell therapy with T cells expressing chimeric antigen receptors (CARs) is an active area of cancer research. (ashpublications.org)

It is known that EpoR can activate mitogenic signaling pathways and can lead to cell proliferation in erythroleukemic cell lines in vitro, various non-erythroid cells, and cancer cells. (wikipedia.org)
5 Institute for Cancer Genetics and Dept of Pathology and Cell Biology, Columbia University, New York, USA. (nih.gov)
Cancer Cell. (cancer.gov)
Currently, crizotinib is the only drug that has been approved for treatment of ALK-rearranged non-small-cell lung cancer (NSCLC). (nih.gov)
furthermore, the expanded γδ T cells were adoptively transferred into late-stage liver and lung cancer patients. (nature.com)
We found that the expanded cells possessed significantly improved immune effector functions, including proliferation, differentiation, and cancer cell killing, both in vitro and in the humanized mouse model. (nature.com)
Furthermore, a phase I clinical trial in 132 late-stage cancer patients with a total of 414 cell infusions unequivocally validated the clinical safety of allogeneic Vγ9Vδ2 T cells. (nature.com)
Among these 132 patients, 8 liver cancer patients and 10 lung cancer patients who received ≥5 cell infusions showed greatly prolonged survival, which preliminarily verified the efficacy of allogeneic Vγ9Vδ2 T-cell therapy. (nature.com)
Previous studies have demonstrated that glycolysis inhibitors reduce the proliferation of non‑small cell lung cancer (NSCLC) cells by interfering with the aerobic glycolytic pathway. (spandidos-publications.com)
However, the mitochondrial oxidative phosphorylation (OXPHOS) pathway in tumor cells has also been implicated in lung cancer metabolism. (spandidos-publications.com)
There are primarily two types of lung cancer: Non-small cell lung cancer (NSCLC) and SCLC, and the former accounts for ~85% of all lung cancer cases ( 3 ). (spandidos-publications.com)
Certain metabolic alterations, also referred to as metabolic reprogramming, are commonly observed in tumor cells and are proposed to be hallmarks of cancer ( 8 ). (spandidos-publications.com)
The most striking and characteristic metabolic alteration in cancer cells is anomalous glucose metabolism and cancer cells tend to utilize glycolysis to obtain energy even under aerobic conditions via a process called 'aerobic glycolysis' ( 9 ). (spandidos-publications.com)
In the 1920s, Otto Heinrich Warburg discovered that cancer cells, unlike normal cells, use the glycolytic pathway to obtain energy for growth even in the presence of oxygen, which is a phenomenon known as 'aerobic glycolysis' or the Warburg effect ( 9 ), and aerobic glycolysis is a common metabolic phenotype in NSCLC ( 11 ). (spandidos-publications.com)
It has been reported that lung cancer cells exhibit upregulated expression of all key glycolytic enzymes [hexokinase 2 (HK2), phosphofructokinase and pyruvate kinase (PK)] ( 13 ), suggesting that the essential enzymes of the aerobic glycolytic pathway have a critical role in the development of lung carcinoma. (spandidos-publications.com)
Lymphomas are the fifth most common form of cancer. (nih.gov)
A better understanding of the changes in cancer cells is leading us to what we hope will be more effective treatment strategies tailored to the genetic profile of each patient's cancer. (nih.gov)
In the early phases of cancer immune surveillance, NK cells directly identify and lyse cancer cells. (frontiersin.org)
Cytokines, cancer vaccines, adoptive cell transfers, and especially checkpoint inhibitors constitute valuable elements in the immunotherapeutic armamentarium. (frontiersin.org)
NK cell infiltration into tumor tissue is associated with better disease prognosis in colorectal cancer, clear cell renal cell carcinoma, and lung carcinomas ( 9 - 11 ). (frontiersin.org)
Additionally, a 11-year prospective cohort study of Japanese inhabitants linked low peripheral-blood NK cell cytotoxicity with increased cancer risk ( 12 ). (frontiersin.org)
Lymphoma, a type of blood cancer, results from the uncontrolled proliferation of lymphocytes. (news-medical.net)
R-CHOP has even been reported to activate certain oncogenes (genes that can cause cancer) and favor a specific subset of cells also referred to as sub-clonal populations. (news-medical.net)
Such cells harbor genetic variations that confer growth advantages and can thus cause recurrent cancer. (news-medical.net)
The mainstay of adjuvant treatment for early-stage, hormone receptor-positive breast cancer has been endocrine therapy, either with tamoxifen and. (ascopost.com)
For patients with advanced non-small cell lung cancer (NSCLC) harboring the ALK gene rearrangement, ceritinib (Zykadia) provided longer progression-free survival than chemotherapy in patients previously treated with chemotherapy and crizotinib (Xalkori), but gastrointestinal toxicity was. (ascopost.com)
CAR-T Cell Therapy Gave Me My Life Back" is reprinted with permission from the Association of Community Cancer Centers. (healthwellfoundation.org)
It works by causing the body's immune system (a group of cells, tissues, and organs that protects the body from attack by bacteria, viruses, cancer cells, and other substances that cause disease) to fight the cancer cells. (medlineplus.gov)
Diseases formerly designated as reticulosis or reticulosarcomatosis are currently classified according to the World Health Organization (WHO)/European Organization for Research and Treatment of Cancer (EORTC) classification (WHO-EORTC classification) for primary cutaneous lymphomas and the WHO classification. (medscape.com)
Acute lymphoblastic leukemia (ALL) is a highly aggressive pediatric cancer that can affect both B cells and T cells. (lu.se)
Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). (medscape.com)
Transcriptomic profiling of T-cell populations in non-muscle invasive and muscle invasive bladder cancer. (lu.se)

Transplant Cell Ther. (canadianhematologytoday.com)

Mycosis fungoides is the most common type, accounting for 60% of CTCLs and almost half of all primary cutaneous lymphomas. (medscape.com)
Successful use of allogeneic stem cell transplantation for treatment-refractory mycosis fungoides]. (medscape.com)

Subsequent differentiation stages (proerythroblast to orthochromatic erythroblast) involve a decrease in cell size and eventual expulsion of the nucleus, and are likely dependent upon EpoR signaling only for their survival. (wikipedia.org)
Together, these data suggest that EpoR in erythroid differentiation may function primarily as a survival factor, while its effect on the cell cycle (for example, rate of division and corresponding changes in the levels of cyclins and Cdk inhibitors) in vivo awaits further work. (wikipedia.org)
To assess whether antigenic engagement of the BCR is required for the ongoing survival of ABC cells, we developed isogenic ABC cells that differed solely with respect to the IgH V region of their BCRs. (arizona.edu)
In competitive assays with wild-type cells, substitution of a heterologous V region impaired the survival of three ABC lines. (arizona.edu)
15 We have recently conducted experiments that demonstrated enhanced in vitro survival of human T cells that were transduced with an ErbB2-specific CAR when the first and third ITAMs of the CD3-ζ domain of the CAR were inactivated. (ashpublications.org)
It is becoming increasingly apparent that tonic signaling through the B cell receptor provides a growth and survival signal in many types of B cell lymphomas, and that disruption of B cell receptor signaling can be lethal to malignant B cells. (wustl.edu)
However, the role of chronic TCR activation in lymphomagenesis and in lymphoma cell survival is still poorly understood. (nebraska.edu)
Using a mouse model, we report that chronic TCR stimulation drove T cell lymphomagenesis, whereas TCR signaling did not contribute to PTCL survival. (nebraska.edu)
In malignant B cells of ABC lymphomas, these receptors provide crucial signals that promote tumor cell survival. (nih.gov)
The area of research for our group is malignant lymphomas - all possible aspects, aiming for the improvement of the quality of life and survival of these patients. (lu.se)

Use of novel methods of molecular monitoring, such as circulating tumor DNA (ctDNA), in lymphoma. (cancer.gov)
However, important advances have been made in understanding that this disease is comprised of at least three molecular subtypes, each derived from B cells at unique stages in their development. (nih.gov)
Their article describes in detail various aspects of tumor biology, including molecular pathways, tumor microenvironment, clonal evolution (selective growth of particular cells) and cell of origin that can help identify potential mechanisms and predictive biomarkers of drug resistance. (news-medical.net)
Molecular signaling pathways control the intracellular decisions of cell growth. (news-medical.net)
Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms. (cdc.gov)

Primary CNS lymphoma in children and adolescents: a descriptive analysis from the international primary CNS lymphoma collaborative group (IPCG). (medscape.com)

ALCL was recognized in 1985, when tumor cells consistently demonstrated labeling by the monoclonal antibody Ki-1, a marker later shown to recognize the CD30 antigen. (medscape.com)
May be normal, or may reveal abnormalities related to organ infiltration (i.e., elevated liver enzymes) or production of substances by the tumor cells. (vin.com)
Therapeutic approaches that target the metabolism of tumor cells have been a popular research topic in recent years. (spandidos-publications.com)
Given the vast differences in metabolism between healthy and tumor cells, there is hope that selective targeting of tumor metabolism may be achieved while limiting toxicity to healthy tissue. (spandidos-publications.com)
First described in 1975, NK cells were initially identified as a distinct sub-population of lymphocytes by their capacity to spontaneously lyse tumor cells ( 1 ). (frontiersin.org)
Agents in this class halt the cell cycle at the G1 phase in tumor cells. (medscape.com)

At present, the most well-established function of EpoR is to promote proliferation and rescue of erythroid (red blood cell) progenitors from apoptosis. (wikipedia.org)
Primary role of EpoR is to promote proliferation of erythroid progenitor cells and rescue erythroid progenitors from cell death. (wikipedia.org)
Induction of proliferation by the EpoR is likely cell type-dependent. (wikipedia.org)
They are caused by an abnormal proliferation of white blood cells, can occur at any age, and are often marked by lymph nodes that are larger than normal, fever, and weight loss. (nih.gov)
Subsequently, inadequate regulation of cell proliferation and defective oncogene and/or suppressor gene expression promote the transition from preneoplastic conditions to neoplasia. (medscape.com)
Non-Hodgkin lymphomas are a heterogeneous group of disorders involving malignant monoclonal proliferation of lymphoid cells in lymphoreticular sites, including lymph nodes, bone marrow, the spleen, the liver, and the gastrointestinal tract. (msdmanuals.com)
In vitro studies based on MCF-7 cell proliferation and induction of vitellogenin in primary culture of rainbow trout hepatocytes. (cdc.gov)

He has carried out studies of stem cell transplantation following high-dose chemotherapy and radiation for acute myelogenous leukemia, one of the most common types of leukemia in adults. (uclahealth.org)
Your dog will receive chemotherapy prior to infusion and then will receive a single dose of UCART-20 cells that will be infused into your dog by an intravenous infusion (into a vein). (upenn.edu)
The process for administering CAR T-cell therapy is complex, with multiple steps including CAR T-cell manufacturing, lymphodepleting chemotherapy, cellular therapy infusion, and management of short-term and long-term toxicities. (ajmc.com)
1 line of systemic therapy in case of participants ineligible for high-dose chemotherapy and autologous Hematopoietic stem cell transplantation (HSCT). (who.int)

After completion of the Run In, an aggressive lymphoma and an indolent lymphoma Dose Expansion cohort may open. (who.int)

She participates in clinical trials of immune effector cells, is actively involved in the implementation of CAR-T in clinical practice in Quebec and is the medical lead of the Quebec immunocellular therapy network. (canadianhematologytoday.com)
Dre Eva Laverdure is a hematologist from the University of Sherbrooke with an interest in lymphoma and CAR-T cell therapy. (canadianhematologytoday.com)
CAR-T Cell therapy: Current Limitations and Potential Strategies. (canadianhematologytoday.com)
Of note, CD19, CD20, CD30, CD33, CD123, and CD269 as ideal targets have shown extraordinary potential for CAR-T cell therapy and other targets such as CD23 and SLAMF7 have brought promising future for clinical trials. (hindawi.com)
Moreover, we will review the disadvantages of CAR-T cell therapy and propose several comprehensive recommendations which might guide its development. (hindawi.com)
To evaluate anti-CD19-CAR-transduced T cells in a murine model of adoptive T-cell therapy, we developed a CAR that specifically recognized murine CD19. (ashpublications.org)
Kenkre, VP & Kahl, BS 2012, ' The future of b-cell lymphoma therapy: The B-cell receptor and its downstream pathways ', Current Hematologic Malignancy Reports , vol. 7, no. 3, pp. 216-220. (wustl.edu)
Chimeric Antigen Receptor (CAR) T cell-therapy is on a roll. (lls.org)
In this context, an objective measure is needed, therefore the index of vaccination against coronavirus disease 2019 (COVID‑19) in B‑cell lymphomas treated with antibody therapy against CD20 (including after the completion of therapy) was examined. (spandidos-publications.com)
A total of 40 patients with B‑cell lymphoma during or after antibody therapy against CD20 were vaccinated twice with the BNT162b2 messenger RNA (mRNA) COVID‑19 vaccine (Pfizer, Inc. and BioNTech SE. (spandidos-publications.com)
As a consequence CD79 is an ideal candidate molecule for B cell-targeted therapy. (nationaljewish.org)
The T cell form of lymphoma is less responsive the therapy, and has a worse long term prognosis than B cell lymphoma. (vin.com)
Despite this heterogeneous response, blood pre-infusion biomarkers predicting responsiveness to CART cell therapy are currently understudied. (frontiersin.org)
With a focused organization and clear priority for advancing a pipeline with the highest probability of success, we believe we are well positioned for long-term success as leaders in the allogeneic T cell therapy field. (businesswire.com)
The Company is advancing the development of ADI-001, the Company's investigational therapy targeting CD20 for the potential treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). (businesswire.com)
Pharmacists are intricately involved in the process of providing CAR T-cell therapy both at the organizational level of budgeting and coordinating therapy and in direct patient care roles providing counseling and support for adverse effect management. (ajmc.com)
Chimeric antigen receptor (CAR) T-cell therapy is designed to enhance the body's immune system to effectively kill malignant cells. (ajmc.com)
1 CAR T-cell therapy pivotal trials demonstrated unprecedented overall response rates (ORRs) and complete responses (CRs) that led to the FDA approval of 5 CAR T-cell products: tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), brexucabtagene autoleucel (brexu-cel), and idecabtagene vicleucel (ide-cel). (ajmc.com)
In addition, challenges related to manufacturing a patient-specific product, need for inpatient administration in a tertiary care setting, high costs and inadequate reimbursement have limited access to CAR T-cell therapy. (ajmc.com)
Editor's Note: This week, Real World Health Care shares an inspirational story of a woman who was diagnosed with lymphoma and received treatment with CAR T-cell therapy. (healthwellfoundation.org)
The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy. (medscape.com)
Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). (medscape.com)
CAR T-cell therapy is coming to myeloma. (medscape.com)

The CAR approach has shown promising results in people with blood cancers such as chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL), however, this is the first time that human CAR T cells will be used in canine patients. (upenn.edu)

Leuk Lymphoma. (cancer.gov)

Besides these, changes in epigenetic modifiers (that induce reversible genetic changes) have also been widely reported in drug-resistant and refractory lymphoma. (news-medical.net)

With few exceptions, stem cell transplantation is usually reserved for patients with aggressive lymphomas after incomplete remission or relapse. (msdmanuals.com)
Up to 12 adult participants with r/r aggressive B-cell NHL may be enrolled into a Run In dose level. (who.int)

Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. (medscape.com)
Likewise, with primary cutaneous lymphomas associated with a poorer prognosis, treatment is different for isolated or grouped lesions than for multiple lesions (see Treatment and Management). (medscape.com)
2. Clinical epidemiology - using data from the Swedish Lymphoma Registry to provide clinically useful real world data on treatment and prognosis, in many cases in collaboration with Nordic colleagues. (lu.se)

Her main interest is improving the care of patients with lymphoma. (canadianhematologytoday.com)
1 In addition, the optimal approach to treating patients with anti-CD19-CAR-expressing T cells is not known. (ashpublications.org)
We obtained lymphoma tissues from HCV-infected lymphoma patients, including some that later regressed upon antiviral treatments. (unipv.it)
We conclude that most lymphomas of HCV-infected patients do not arise from B cells aimed at eliminating the virus. (unipv.it)
His approach is to put into clinical trials new treatments developed in the laboratory for patients with blood stem cell diseases or cancers of the bone marrow and blood. (uclahealth.org)
2004). Adundant expression of P2RY8 has been demonstrated in bone marrow CD34+ cells in leukaemic patients (Fujiwara et al. (atlasgeneticsoncology.org)
Twenty-six patients were infused with CART cells (median 81 days after leukapheresis) and were analyzed for the overall response (OR) 3 months later. (frontiersin.org)
Commenting on this talk during the discussion afterward, Youn Kim, MD , of Stanford University School of Medicine, Stanford, California, said: "At our center, we use high-throughput sequencing of T-cell receptors daily in patients with cutaneous T-cell lymphomas, and it is a billable. (ascopost.com)
Results: There was a concurrent accumulation of circulating peripheral IL-17-producing CCR6+ Th cells and FoxP3+ Tregs in patients with dcSSc. (uni-wuerzburg.de)
Martí-Carvajal AJ, Cardona AF, Lawrence A. Interventions for previously untreated patients with AIDS-associated non-Hodgkin's lymphoma. (medscape.com)
[ 1 , 2 ] They can be defined as lymphoproliferative skin infiltrates of T-cell, B-cell, or natural killer cell lineage, which primarily occur in and remain confined to the skin in most patients, without detectable extracutaneous manifestations at diagnosis. (medscape.com)

Peripheral T cell lymphomas (PTCLs) represent a significant unmet medical need with dismal clinical outcomes. (nebraska.edu)
Therefore, we developed a novel formula to improve the expansion of peripheral γδ T cells from healthy donors. (nature.com)
γδ T cells, specifically the Vγ9Vδ2 subset, which is the dominate subset among γδ T cells in human peripheral blood, recognize target cells in a human leukocyte antigen (HLA)-independent manner. (nature.com)
Very severe infiltration may cause myelophthisis (crowding out of normal marrow elements by malignant cells) and may be manifested as peripheral cytopenias and lymphoid leukemia. (vin.com)
2007). However P2RY8 expression appears to be down-regulated during leucocyte differentiation: normal, mature peripheral blood leucocytes have been shown to have minimal expression, while an undifferentiated promyelocytic leukaemia cell line was shown to have moderate expression of P2RY8 that was down-regulated with induction of granulocyte differentiation (Adrian et al. (atlasgeneticsoncology.org)
Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases. (medscape.com)
Most lymphomas are nodal with variable involvement of the bone marrow and peripheral blood. (msdmanuals.com)

Clin Lymphoma Myeloma Leuk. (moffitt.org)

Allogeneic hematopoietic stem cell transplantation is the only potentially curative treatment for myelofibrosis. (ascopost.com)

Anti-CD19-CAR-transduced T cells had superior antilymphoma efficacy compared with the anti-CD19 monoclonal antibody from which the anti-CD19 CAR was derived. (ashpublications.org)
Current technologies for treatment of many lymphomas, leukemias, transplant rejection and some autoimmune disorders include monoclonal antibodies (mAb) that target and deplete B cell populations. (nationaljewish.org)
Age-related clonal hematopoiesis and monoclonal B-cell lymphocytosis/chronic lymphocytic leukemia: a new association? (haematologica.org)

Cutaneous T-cell lymphoma (CTCL) (see the image below) is a heterogeneous group of lymphoproliferative disorders characterized by localization of neoplastic T lymphocytes to the skin, with no evidence of extracutaneous disease at the time of diagnosis. (medscape.com)
Also, the term "primary cutaneous CD4 + small/medium T-cell lymphoma" was changed to "primary cutaneous CD4 + small/medium T-cell lymphoproliferative disorder" because of its indolent clinical behavior and uncertain malignant potential. (medscape.com)
PC-ALCL is one of the primary cutaneous CD30 + T-cell lymphoproliferative disorders, a wide spectrum of disease, with lymphomatoid papulosis (LyP) at the benign end of the spectrum and PC-ALCL at the malignant end. (medscape.com)

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. (nature.com)

The most active T cell endogenous inhibitory pathway is the immunoglobulin superfamily such as CD28/cytotoxic T lymphocyte antigen-4 (CTLA-4): B7-1/B7-2 receptor/ligand grouping, which plays a central role in coordinating immune responses [ 7 , 8 ]. (hindawi.com)

Most CARs that are being evaluated in current clinical and preclinical studies recognize self-antigens that are expressed by normal tissues as well as malignant cells. (ashpublications.org)
Such malignant cells proliferate uncontrollably leading to impairment of normal blood cell function, and in advanced cases leads to kidney impairment and bone destruction. (lls.org)
Vγ9Vδ2 T cells recognize pyrophosphates secreted by many microbes or overproduced by malignant cells in the context of butyrophilin 3A1 molecules. (nature.com)

Efforts at using NK cells as antitumor agents began over two decades ago, but recent advances in elucidating NK cell biology have accelerated the development of NK cell-targeting therapeutics. (frontiersin.org)
Current Research and Scholarly Interests We employ an interdisciplinary approach to studies of biological systems, combining synthetic chemistry with biochemistry, cell biology, and structural biology. (stanford.edu)

for example, there are inconsistent views 24 on the intratumoral γδ T-cell signature as the most favorable prognostic biomarker 25 of cancers and discussions on the pro- and antitumor activities of γδ T cells. (nature.com)
Renal cell carcinoma is one of the most common cancers in the urinary system, causing over 140,000 deaths worldwide each year[ 1 ]. (medsci.org)
This is a new cell-based treatment for dogs with B cell cancers such as B cell lymphoma and B cell leukemia. (upenn.edu)
The purpose of this study is to determine the safety, persistence and effectiveness of B cell specific UCART cells to target and kill B cells in dogs with B cell cancers. (upenn.edu)
Workers in the rubber-manufacturing industry have an increased risk for leukaemia, lymphoma, and cancers of the urinary bladder, lung, and stomach. (cdc.gov)

As a clinical investigator, her research focuses upon improving treatment outcomes of lymphomas through novel therapeutics, identification of biomarkers to predict responses and interrogating mechanisms of treatment resistance. (moffitt.org)

Due to their HLA-independent mode of action, allogeneic Vγ9Vδ2 T cells can be considered for clinical application. (nature.com)

Anatomy30

Organisms15

Diseases43

Chemicals and Drugs92

Analytical, Diagnostic and Therapeutic Techniques and Equipment36

Phenomena and Processes43

Disciplines and Occupations1

Information Science5

Health Care7

Anaplastic large ce2

Large B cell lym10

Multiple myeloma9

Mantle cell lym2

Antigen receptor T-cell therapy3

Diffuse1

Hodgkin Lymphoma19

Tumors10

Malignancies13

Immunotherapy11

DLBCL8

Follicular8

Tyrosine kinase5

Treatment of cutaneous4

Marginal zone lymphomas2

Protein9

Therapies10

Cytokine4

Cutaneous B-Cell Lym2

Chimeric Antigen Receptors1

Cancer32

Transplant Cell Ther1

Mycosis fungoides2

Survival10

Molecular5

Primary CNS Lymp1

Tumor cells6

Proliferation7

Chemotherapy4

Indolent Lymphoma1

Therapy23

Acute1

Leuk Lymphoma1

Refractory lymphoma1

Aggressive2

Prognosis3

Patients11

Peripheral7

Myeloma1

Stem cell transplant1

Monoclonal3

Lymphoproliferative3

Kinase1

Pathway1

Malignant cells3

Biology2

Cancers5

Biomarkers1

Allogeneic1